Tags : axitinib

Regulatory

Merck Receives EU’s CHMP Positive Opinion for its Zerbaxa (ceftolozane

Shots: The positive CHMP opinion of Zerbaxa (3gm) is based on P-III ASPECT-NP study assessing Zerbaxa in patients with hospital-acquired pneumonia including ventilator-associated pneumonia. The EC will review CHMP’s opinion to grant centralized marketing authorization to the combination therapy The CHMP positive opinion of Keytruda + Inlyta is based on P-III KEYNOTE 426 study which […]Read More